Actinium Pharmaceuticals, Inc. ATNM · Stock Open Actinium Pharmaceuticals, Inc. in new tab
Actinium Pharmaceuticals, Inc. Analysis (ATNM)
Is Actinium Pharmaceuticals, Inc. a good investment? Actinium Pharmaceuticals, Inc. (ATNM) is currently trading at 1.15 USD. Market analysts have a consensus price target of 3.60 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 3.43. This relatively low multiple may signal that Actinium Pharmaceuticals, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Actinium Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.53.
Investor FAQ
Does Actinium Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Actinium Pharmaceuticals, Inc.?
Actinium Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of 0.35.
Company Profile
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 11, 2020 | 0.03 |
Community Discussion